Kaynaklar
1. GOLD. Global Initiative for Chronic Obstructive Lung
Disease. Global strategy for the diagnosis, management,
and prevention chronic obstructive pulmonary disease
2006. MRC Vision Inc 2006: 1-88.
2. Menezes AM, Perez-padilla R, Jardim JB, et al. Chronic
obstructive pulmonary disease in five Latin American
cities (The PLATINO study): a prevalence study. Lancet
2005; 366; 1875-1881.
3. Buist AS, McBurnei MA, Vollmer WM, et al. International
variation in the prevalence of COPD (The BOLD study):
a population-based prevalence study. Lancet 2007; 370:
741-750.
4. Kocabas A, Hancioglu A, Turkyilmaz S, et al. Prevalence
of COPD in Adana, Turkey (BOLD-Turkey Study). Proc
Am Thorac Soc 2006; 3 (Suppl): A543.
5. Hansen JE, Sun XG, Wasserman K. Spirometric criteria
for airway obstruction: use percentage of FEV1/FVC
ratio below the fifth percentile, not <70%. Chest 2007;
131: 349-355.
6. Mannino DM, Buist AS, Vollmer WM. Chronic
obstructive pulmonary disease in the older adult: what
defines abnormal lung function? Thorax 2007; 62:
237-241.
7. Chapman KR, Mannino DM, Soriano JB, et al.
Epidemiology and costs of chronic obstructive
pulmonary disease. Eur Respir J 2006; 27: 188-207.
8. Ramirez-Venegas A, Sansores RH, Perez-Padilla R, et al.
Survival of patients with chronic obstructive pulmonary
disease due to biomass smoke and tobacco. Am J Respir
Crit Care Med 2006; 173: 393-397.
9. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen
A, Nordestgaard BG. C-reactive protein as a predictor
of prognosis in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2007; 175: 250-255.
10. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone
on systemic markers of inflammation in chronic
obstructive pulmonary disease. Am J Respir Crit Care
Med 2004; 170: 760-765.270 • Aralık 2009 • Gülhane Tıp Derg Kartaloğlu
11. Walker PP, Mitchell P, Diamantea F. Warburton CJ,
Davies L. Effect of primary-care spirometry on the
diagnosis and management of COPD. Eur Respir J 2006;
28: 945-952.
12. Rabe KF, Beghe B, Luppi F, Fabbri LM. Update in chronic
obstructive pulmonary disease 2006. Am J Respir Crit
Care Med 2007; 175: 1222-1232.
13. Gamble E, Grootendorst DC, Hattotuwa K, et al. Airway
mucosal inflammation in COPD is similar in smokers
and ex-smokers: a pooled analysis. Eur Respir J 2007;
30: 467-471.
14. Hogg JC, Chu F, Utokaparch S, et al. The nature of smallairway obstruction in chronic obstructive pulmonary
disease. N Engl J Med 2004; 350: 2645-2653.
15. Zandvoort A, van der Geld YM, Jonker MR, et al. High
ICAM-1 gene expression in pulmonary fibroblasts
of COPD patients: a reflection of an enhanced
immunological function. Eur Respir J 2006; 28:
113-122.
16. Koch A, Gaczkowski M, Sturton G, et al. Modification
of surface antigens in blood CD8+ T-lymphocytes in
COPD: effects of smoking. Eur Respir J 2007; 29: 42-50.
17. O’Donnell RA, Peebles C, Ward JA, et al. Relationship
between peripheral airway dysfunction, airway
obstruction, and neutrophilic inflammation in COPD.
Thorax 2004; 59: 837-842.
18. Rytilä P, Plataki M, Bucchieri F, Uddin M, Nong G,
Kinnula VL, Djukanovic R. Airway neutrophilia in
COPD is not associated with increased neutrophil
survival. Eur Respir J 2006; 28: 1163-1169.
19. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic
obstructive pulmonary disease. Oxidative Stress Study
Group. Am J Respir Crit Care Med 1997; 156: 341-357.
20. Kinnula VL, Ilumets H, Myllärniemi M, Sovijärvi A,
Rytilä P. 8-Isoprostane as a marker of oxidative stress
in nonsymptomatic cigarette smokers and COPD. Eur
Respir J 2007; 29: 51-55.
21. Hansel TT, Barnes PJ. An atlas of chronic obstructive
pulmonary disease COPD. New York: The Parthenon
Pub, 2004: 135-190.
22. Kartaloglu Z. KOAH’ta Tedavi ve Korunma. Klinik
Aktüel Tıp Solunum Formu 2007; 1: 31-41.
23. Calverley PM, Anderson JA, Celli B, et al. Salmeterol
and fluticasone propionate and survival in chronic
obstructive pulmonary disease. N Engl J Med 2007; 356:
775-789.
24. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory
effects of salmeterol/fluticasone propionate in chronic
obstructive lung disease. Am J Respir Crit Care Med
2006; 173: 736-743.
25. Wedzicha JA, Calverley PM, Seemungal TA, Hagan
G, Ansari Z, Stockley RA. The Prevention of COPD
exacerbations by salmeterol/fluticasone propionate or
tiotropium bromide. Am J Respir Crit Care Med 2008:
177: 19-26.
26. Aaron SD, Vandemheen KL, Fergusson D, et al.
Tiotropium in combination with placebo, salmeterol,
or fluticasone-salmeterol for treatment of chronic
obstructive pulmonary disease: a randomized trial. Ann
Intern Med 2007; 146: 545-555.
27. Bailey WC, Tashkin DP. Pharmacologic therapy: novel
approaches for chronic obstructive pulmonary disease.
Proc Am Thorac Soc 2007; 4: 543-548.
28. Hanania NA, Donohue JF. Pharmacologic
interventions in chronic obstructive pulmonary
disease: bronchodilators. Proc Am Thorac Soc 2007; 4:
526-534.
29. Fabbri LM, Rabe KF. From COPD to chronic systemic
inflammatory syndrome? Lancet 2007; 370: 797-799.
30. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and
osteoporosis in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2007; 175: 1259-1265.
31. Mancini GBJ, Etminan M, Zhang B, Brophy JM.
Reduction of morbidity and mortality by statins,
angiotensin-converting enzyme inhibitors, and
angiotensin receptor blockers in patients with chronic
obstructive pulmonary disease. J Am Coll Cardiol 2006;
47: 2554-2560.
32. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is
associated with reduced mortality in COPD. Eur Respir
J 2007; 29: 279-283.
33. Keddissi J, Younis W, Chbeir E, Daher N, Dernaika T,
Kinasewitz G. The use of statins and lung function
in current and former smokers. Chest 2007; 132:
1764-1771.
34. Skillrud DM, Offord KP, Miller RD. Higher risk of lung
cancer in chronic obstructive pulmonary disease: a
prospective, matched, controlled study. Ann Intern
Med 1986; 105: 503-507.
35. Coussens LM, Werb Z. Inflammation and cancer. Nature
2002; 420: 860-867.
36. Kunter E, Ilvan A, Ozmen N, et al. Effect of corticosteroids
on hemostasis and pulmonary arterial pressure during
chronic obstructive pulmonary disease exacerbation.
Respiration 2008; 75: 145-154.
37. Parimon T, Chien JW, Bryson CL, McDonell MB,
Udris EM, Au DH. Inhaled corticosteroids and risk of
lung cancer among patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2007;
175: 712–719.
38. Miller YE, Keith RL. Inhaled corticosteroids and lung
cancer chemoprevention [editorial]. Am J Respir Crit
Care Med 2007; 175: 636–637.
39. Soriano JB, Visick GT, Muellerova H, Payvandi N,
Hansell AL. Patterns of comorbidities in newly diagnosed
COPD and asthma in primary care. Chest 2005; 128:
2099-2107.
40. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled
corticosteroid use in COPD and the risk of hospitalization
for pneumonia. Am J Respir Crit Care Med 2007; 176:
162-166.
41. Woodhead M. Inhaled corticosteroids cause pneumonia
...or do they? Am J Respir Crit Care Med 2007; 176:
111-112.
42. Kiri V, Visick G, Chigbo C, Hagan G, Muellerova H,
Davis K. Assessing the incidence pattern of pneumonia
among COPD patients with or without exposure to
inhaled steroids. Eur Respir J 2007; 30 (Suppl 51): 628.
Thank you for copying data from http://www.arastirmax.com
